Replies to post #40258 on Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Recent evidence indicates that vasoactive intestinal peptide (VIP), an anti-inflammatory neuropeptide with therapeutic potential in various immune disorders, participates in maintaining immune tolerance by a novel mechanism of inducing the generation of Treg cells.

https://www.cell.com/trends/molecular-medicine/comments/S1471-4914(07)00067-6

WILL VIP BECOME THE STANDARD OF CARE IN IMMUNOTHERAPY???